SPOTLIGHT: Portola raises $46M


Portola Pharmaceuticals announced that it has raised $46 million in series B financing that will be used to develop the company's cardiovascular therapies, specifically, moving an oral Factor Xa inhibitor into phase II trials. The round was led by Advanced Technology Ventures (ATV) and Alta Partners. As a result of the financing, Jean George of ATV and Farah Champsi of Alta Partners will be joining the board of directors. Release

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.